Reason for performing study: Trimetoquinol (TMQ) is a potent -adrenoceptor agonist bronchodilator used in human medicine but has not been evaluated for potential use as a therapeutic agent for horses with 'heaves'. Objectives: To assess the pharmacodynamics of TMQ in horses with 'heaves' to determine potential therapeutic effects. 
Introduction
Trimetoquinol (TMQ) (1-(3',4',5'-trimethoxybenzyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, molecular weight 345) is the prototype tetrahydroisoquinoline pharmaceutical and is marketed in Japan (Inolin) 1 as an oral bronchodilator for the treatment of asthma and other respiratory conditions in man (Iwasawa 1967) . It has one centre of chemical asymmetry; the S(-)-isomer is a nonselective (Konkar et al. 1999) -adrenoceptor agonist (Iwasawa 1967) . In contrast, the R(+)-isomer possesses thromboxane A 2 /prostaglandin H 2 antagonist activity (Shin et al. 1993) . Inolin is the S(-)-isomer of TMQ, and is therefore primarily a -adrenoceptor agonist.
'Heaves' is an inflammatory and obstructive airway equine disease and therapeutic agents used for treatment include 2 -adrenoceptor agonists (long and short-acting, e.g. clenbuterol, albuterol), anticholinergics (e.g. ipratropium bromide, glycopyrolate) and corticosteroids (e.g. dexamethasone, beclomethasone). Depending on the agent, these drugs are administered by inhalation, per os, intratracheally (i.t.) or i.v. Different agents are effective for different aspects of 'heaves' e.g. albuterol, a short acting bronchodilator (duration of action about 1 h) with rapid onset of action (about 5 min) (Derksen et al. 1999) , is useful in an acute episode, clenbuterol is longer lasting, improves mucociliary clearance and has mucolytic actions (Turgut and Sasse 1989) and corticosteroids are used to treat inflammation. Treatment should include short-term attenuation of bronchoconstriction, reduction of inflammation and management or prophylaxis to prevent further exacerbations. Bronchodilators should not be used as the sole therapy since they neither suppress airway inflammation nor reduce airway hyper-reactivity. However they are important emergency agents to be administered when the horse is in acute respiratory distress.
An evaluation of the pharmacodynamics of TMQ in horses with 'heaves' is reported here in order to establish the effective and safe doses of this agent by the i.v. and i.t. routes. Because TMQ is a -adrenoceptor agonist, we investigated its effects on heart rate, airway function, sweating and temperature regulation, all of which can be modified by -adrenoceptor activation. This information is fundamental to assess TMQ's potential for use as a therapeutic agent.
Materials and methods

Horses
For dose-response and duration of action experiments, approved by the All University Animal Use and Care Committee of Michigan State University, 6 horses with a history of 'heaves' were used. They included 5 mares and 1 gelding of various breeds, age 17-29 years, weighing 483-570 kg. Horses were maintained on pasture and their diet supplemented with pelleted alfalfa feed as necessary. While on pasture, the animals presented no signs of airway obstruction but, when housed in stalls, bedded on straw and fed hay, they developed characteristic clinical signs of 'heaves'.
For the temperature change experiments, 6 mature Thoroughbred mares weighing 481-525 kg were used from the University of Kentucky herd. They were fed b.i.d. with grass hay and pelleted feed (12%), which was a 50:50 mixture of oats and alfalfa-based protein. During research protocols, horses were provided with water and hay ad libitum. They were managed according to the rules and regulations of the Institutional Animal Care Use Committee at the University of Kentucky, which also approved the experimental protocol. A routine clinical examination was performed before each experiment to assure that the animals were healthy.
TMQ acquisition and validation
TMQ was a gift from Tanabe Seiyaku Co., Ltd 1 , with a certificate of analysis indicating an estimated purity of 99.3-100.9%, confirmed by in-house GC-MS (gas chromatography-mass spectrometry) evaluation of a BSTFA + 1% TMCS (N,O-bis-(trimethylsilyl) trifluoroacetamide + 1% trimethylchlorosilane) 2 derivatised sample.
Heart rate
Heart rate (HR) was recorded by a heart rate computer (Hewlett Packard M1401A Digital UHF Telemetry System) 3 . The 3 electrodes were placed over the heart at the level of the left elbow, on the withers and on the neck of the horse.
Maximal change in pleural pressure ( Pplmax)
Maximal change in pleural pressure ( Pplmax) was estimated by use of an oesophageal balloon catheter inserted into the distal third of the oesophagus so that the balloon was between heart and diaphragm (Robinson et al. 2000) . The catheter was connected to a pressure transducer (Model DP/45-34) 4 and recording system (Model Dash 18) 5 The position of the balloon was adjusted to obtain maximal change in pleural pressure ( Pplmax) during tidal breathing. The pressure transducer was calibrated before each study against a water manometer.
Rectal and skin temperatures
Skin and rectal temperatures were measured following the protocol described by Harkins et al. (1996) : skin temperature with a surface thermistor (Model 409B) 6 attached to the chest wall with a skin adhesive (Vetbond) 7 and rectal temperature with a general purpose thermistor (Model 401) 6 placed 50 cm into the rectum and secured with adhesive tape to the tail after faecal content was removed. The thermistors were attached to a digital thermometer (Model 8402) 8 and temperatures recorded 15 min before, immediately before, and 2, 5, 10, 15, 20, 30, 40, 50, 60, 75, 90 and 120 min after TMQ administration.
Side effects of TMQ
Side effects were scored as follows: 1) Sweating: 0 = no sweat and cool flanks; 1 = warm and humid flanks; 2 = warm flanks and wet hands after stroking flanks; 3 = flanks visibly wet; and 4 = sweat dripping from flanks. 2) Agitation: 0 = calm horse with no temperament change; 1 = restless; 2 = anxious appearance, or ear pinnae retracted back or eyes wide open; 3 = pawing the ground. 3) Muscle trembling: 0 = no trembling; 1 = intermittent trembling of flanks; 2 = constant trembling of flanks; 3 = sustained trembling of flanks and some trembling of other parts of the body.
Experimental design
Cumulative dose-response to TMQ: For the experiments in 'heaves'-affected horses, TMQ was dissolved in ethanol to yield a 1 mg/ml stock solution; this stock was then diluted with saline into the required doses yielding a 2 ml final volume for i.v. jugular and i.t. Horses were brought from the pasture into the stable, bedded on straw and fed hay. A technician observed horses daily and assigned a clinical score (0-8) to evaluate the severity of airway obstruction (Rush et al. 1998; Robinson et al. 2000) . When the score was 5 or greater, the Pplmax was measured. When Pplmax exceeded 15 cmH2O, horses qualified for entry into the protocol. Saline and increasing doses of TMQ were administered at 15 min intervals. Maximal change in pleural pressure ( Pplmax) and heart rate (HR) were recorded continually and peak HR and lowest Pplmax during the 15 min period were used to generate a cumulative dose-response curve. Side effects were also recorded. The experiment was terminated and the final response was considered the maximum effective response when one of the following occurred: 2 consecutive doses did not cause any further decrease in Pplmax, HR exceeded 220 beats/min or the side effects were considered uncomfortable for the horse.
Duration of action of TMQ:
This crossover experiment was conducted 2 weeks after measurement of the dose response. A 1 mg/kg stock solution of TMQ in ethanol was diluted in saline to achieve a concentration of 0.2 µg/kg bwt for i.v. bolus administration and 2 µg/kg bwt for i.t. administration. Final administration volume was 2 ml for either route. In negative control experiments horses received 2 ml saline, i.v. or i.t.
HR and Pplmax were recorded at times 0 (before drug administration), and 1, 3, 6, 10, 15, 20, 30 and 45 min, and 1, 2, 4 and 6 h after i.v. administration of 0.2 µg/kg bwt TMQ or saline. For the i.t. administration, measurements were made at times 0 (before drug administration), and 3, 6, 9, 12, 16, 20, 25, 30 and 45 min, and 1, 2, 4 and 6 h after administration.
Rectal and skin temperature
In a crossover experiment conducted at the University of Kentucky, 6 healthy horses were dosed i.v. with saline and TMQ at doses 2 and 8 µg/kg bwt. Skin and rectal temperatures were recorded at times: 10 min prior to administration, immediately before, and 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 150 and 180 min after administration. Each horse received only one treatment each day. The minimum time allotted between treatments was 3 days. This experiment was performed before the determination of the dose-response.
Statistical analysis
A repeated measures ANOVA was used to evaluate the effect of TMQ dose and time and their interactions. The confidence interval was set at 95% and results were significantly different when P<0.05. Results are presented as mean and the 95% confidence interval (95% CI).
Results
Cumulative dose-response
Heart rate: Heart rate before administration of i.v. TMQ was 46 beats/min (95% CI: 27.11, 64.89). The HR increased significantly within 1 min of TMQ administration to 71.33 beats/min (95% CI: 52.44, 90.22) at a dose of 0.01 µg/kg bwt (P<0.001). As the TMQ dose was increased, HR increased progressively. At the highest dose of TMQ, administered i.v. (0.2 µg/kg bwt), HR was 162.8 beats/min (95% CI: 143.91, 181.69) and was still increasing; there was a significant increase (P<0.0001) in HR between 0.1 and 0.2 µg/kg bwt ( Fig 1A) .
Heart rate also increased following i.t. administration of TMQ (Fig 1B) . Baseline HR, prior to i.t. TMQ administration, was 40.83 beats/min (95% CI: 32.56, 49.1). The increase first became significant at a dose of 0.5 µg/kg bwt, when the HR was 60.67 beats/min (95% CI: 52.4, 68.94) (P<0.001). At the highest dose administered, HR was 145.7 beats/min (95% CI: 137.43, 153.97) and was significantly higher than at 1 µg/kg (P<0.0001). Whereas the increase in HR occurred within seconds of IV administration of TMQ, the increase was delayed for 6-8 min after i. (Fig 2A) .
In 3 horses, i.t. administration of 0.01 and 0.02 µg/kg bwt TMQ was followed by an increase in Pplmax. Higher doses caused a decrease in Pplmax back to baseline. In the other 3 horses, no increase in Pplmax occurred and i. (Fig 2B) (P>0.05) . Figure 3 
Side effects
Most horses started to show side effects of i.v. TMQ after a dose of 0.02 µg/kg bwt (Table 1) . Sweating was the most observable response with score reaching 4 in all horses at a TMQ dose of 0.1 µg/kg bwt. The scores for muscle trembling and agitation were considerably less than for sweating, but both increased with TMQ dose. Side effects were no longer evident 1-2 h after the last dose of TMQ. With i.t. administration, sweating appeared at a TMQ dose of 0.5 µg/kg bwt, trembling and agitation at 1 µg/kg bwt ( Table 1) . (Fig 5B) . There was a secondary decrease in Pplmax 4 and 6 h after TMQ administration (P<0.05). Saline i.t. had no effect on Pplmax (P>0.05).
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Rectal and skin temperature
We assessed skin and rectal temperature before and after i.v. administration of saline, and 2 and 8 µg/kg bwt TMQ. Rectal temperature was not significantly affected by TMQ administration (overall mean ±s.d.: 40.12ºC ± 0.423) (P>0.05). Skin temperature decreased significantly at 60 and 90 min (Table 2 ) (P<0.05). Saline administration had no effect on skin temperature.
Discussion
The scope of this study was to evaluate the efficacy of TMQ, a -agonist, as a bronchodilator in horses and also to assess the possibility of side effects. We therefore evaluated the bronchodilator and cardiac responses to TMQ following its i.v. and i.t. administration in horses with 'heaves'. Because bronchospasm is a defining feature of this disease, these horses were used to determine if TMQ is a bronchodilator. The results presented here showed that TMQ produced bronchodilation in horses with 'heaves'. In general the effects were fast-acting and short-lived. By the i.v. route, it was up to 100 fold more potent than by i.t. Side effects included tachycardia, sweating, agitation and muscle tremors.
The results of the study confirm that TMQ administered i.v. or i.t. is a nonspecific -adrenoceptor agonist. While bronchodilation and sweating are initiated via 2 -adrenoceptor activation, tachycardia is initiated by activation of 1 -adrenoceptors. Inspection of Figures 1 and 2 indicates that first significant effects of i.v. TMQ on HR and Pplmax occurred at the same dose (0.01 µg/kg bwt). Also the i.v. dose of TMQ producing half maximal effects was similar (0.02-0.05 µg/kg bwt) for HR and bronchodilation ( Pplmax). There are differing reports about TMQ -adrenoceptor selectivity (Farmer et al. 1970; Feller et al. 1975; Fedyna et al. 1987; Konkar et al. 1999) , some report a selective 2 -adrenoceptor activation, and some a nonselective -adrenoceptor activation, our results favour nonselectivity.
To be optimally active by the i.t. route, medication should have potent respiratory effects and relatively fewer systemic effects. However, when administered by the i.t. route at doses equivalent to those administered i.v., TMQ produced no measurable pulmonary responses and no apparent cardiac responses. Increasing the dose showed that TMQ, by the i.t. route, was up to 100 x less potent in producing pharmacological responses than by the i.v. route. Furthermore, even at the highest doses administered, TMQ was less efficacious i.t. than i.v. in causing bronchodilation. The percent reduction in Pplmax for i.v. route was 41%, whereas for the i.t. route it was only 28% (Fig 3) . One possible explanation is that TMQ, administered i.t. in a small volume (2 ml), deposits on the tracheal mucosa, is absorbed through it, and then passes through the peripheral circulation before it causes an effect in the airways. This is probably the reason why i.t. TMQ elicited an effect only after 6-8 min, compared to 1-2 min by the i.v. route. We also noticed that by the i.t. route, low doses of TMQ produced an increase in Pplmax (more bronchospasm) in 3 horses (mean increase 48%, or 12 cmH 2 O in these 3 horses). However, this increase was not statistically significant. By the i.t. route, only at the 2 higher doses did TMQ produce significant decreases in Pplmax. One possibility is that the drug is an irritant that provokes bronchospasm, and the lower concentrations of TMQ cannot alleviate it. This may be due to the nonspecific hyperresponsiveness characteristic of 'heaves', in which TMQ, an alkaloid, saline and residues of ethanol may have acted as a stimulus to further contract the airway smooth muscles. With higher doses, the drug was able to overcome the irritant effect and caused bronchodilation, seen by decreased Pplmax.
When administered in a single bolus dose by the i.v. route (0.2 µg/kg bwt), the onset of action of TMQ was rapid both in increasing the HR, causing bronchodilation and initiating sweating. Peak responses occurred in less than 3 min. The peak response occurred slightly later (9 min) when TMQ was administered i.t. (2 µg/kg bwt). The duration of effect of TMQ was short by these routes, with HR and Pplmax returning to basal levels within 2 h, comparable to albuterol (Derksen et al. 1999) . With both i.v. and i.t. routes of administration, there was an intriguing secondary decrease in Pplmax without an accompanying increase in HR 2-6 h after TMQ administration. This may be explained if serological analyses show that a 2-adrenoceptor active metabolite is being re-released into circulation, perhaps from fat tissues. It is unlikely that this decrease is due to a circadian change in the severity of airway obstruction because there was no significant decrease when horses were treated with saline.
Trimetoquinol was highly active on the cardiovascular system, and it also produced agitation, sweating and muscle trembling in horses, which was not surprising since these are the same responses elicited by epinephrine and other sympathomimetic agents (Hoffman 2001 ) and all 2-agonists. The possibility of developed tolerance to these side effects following multiple administrations, as happens with clenbuterol (Erichsen et al. 1994) , was not investigated.
In a pilot experiment, it was noticed that sweating was one of the responses observed following TMQ administration. We, therefore, followed the changes in rectal and cutaneous temperatures after i.v. TMQ. Rectal temperature was used because measuring blood temperature in the pulmonary artery is an invasive technique, despite the fact that it may be the best estimate of core temperature (Tomasic 1999) . Tomasic and Nann (1999) showed that mean rectal temperature and mean core temperature were not significantly different from each other in anaesthetised horses. While there are limitations to measuring rectal temperature as a reflection of core temperature, we have described previously how the sweat response induced by isoxsuprine administration produces a substantial decline in rectal temperature (Harkins et al. 1996) and, by extrapolation, core temperature. Since the technique utilised previously for isoxsuprine and now for TMQ was the same, had a drop in core temperature occurred following TMQ administration, it would probably have been detectable rectally. However, TMQ-induced sweating was associated with decreased skin temperature but no significant reduction in rectal temperature. It may be that TMQ-induced agitation and muscle trembling increased metabolic heat production and prevented the decrease in rectal temperature in the face of sweating. Trimetoquinol also has been reported to activate 3 -adrenoceptors that promote lipolysis and thereby increases heat production (Konkar et al. 1999) .
In conclusion, although TMQ is a highly potent agent, it is not a very efficacious bronchodilator when compared to atropine (Robinson et al. 1993) . Furthermore, the presence of side effects of TMQ precludes its clinical use by the i.v. and i.t. routes. Nevertheless, when administered by nebulisation in man (Yamamura et al. 1968 ) TMQ produced no side effects and yielded a clinically useful bronchodilation. Even though by the i.t. route TMQ elicited an inferior response when compared to the i.v. route, a small dose administered by aerosol may be very effective with symptomatic treatment of 'heaves'. For these reasons, we plan to investigate the efficacy of TMQ as an aerosol in horses for symptomatic treatment of 'heaves'.
